Trial Profile

A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Acral lentiginous melanoma; Malignant melanoma
Focus Therapeutic Use
Acronyms OPTIMIzE
Sponsors Bristol-Myers Squibb

Most Recent Events

17 May 2022 Status changed from active, no longer recruiting to completed.
27 Apr 2020 Planned End Date changed from 30 Sep 2021 to 31 May 2021.
27 Apr 2020 Planned primary completion date changed from 31 Oct 2020 to 31 Jul 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com